Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
| ▸ | TPMT | P51580 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.67 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | THRA | P10827 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122418 | 0.98 | TSHR (0.78) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL5492174 | 0.97 | TSHR (0.76) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL8085474 | 0.95 | TSHR (0.78) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL18682279 | 0.94 | PLA2G4B (0.74) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL9307551 | 0.94 | PLA2G4B (0.74) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL7751323 | 0.94 | TSHR (0.68) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL16077692 | 0.94 | PLA2G4B (0.74) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL19970622 | 0.94 | TSHR (0.68) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL2312195 | 0.94 | PLA2G4B (0.74) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL7273205 | 0.94 | PLA2G4B (0.74) | TSHRCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2020006722-A1 | CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | PBDC1, BRD2, CD79B | TSHR 2307/4885CA12 2217/4885CA1 1942/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | TSHR 3815/4885CA12 372/4885CA1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.